Myeloid and Monocytic Leukemia, Phase II

A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

Volunteers
Health Professionals

What is the purpose of this trial?

The goal of this clinical trial is to learn if participants treated with the experimental drug cusatuzumab added to venetoclax and azacitidine works to treat acute myeloid leukemia (AML) compared to venetoclax and azacitidine. Venetoclax and azacitidine are drugs commonly used to treat AML in patients that are unable to receive chemotherapy to treat AML. The main question the clinical trial aims to answer is does cusatuzumab added to venetoclax and azacitidine prolong the length of time participants live compared to venetoclax and azacitidine?

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Farah Fasihuddin

farah.fasihuddin@yale.edu

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Amer Zeidan, MBBS, MD
Professor of Internal Medicine (Hematology); Chief, Division of Hematologic Malignancies; Director, Early Therapeutics Research, Yale Cancer Center; Director, Leukemia and Myeloid Malignancies Program, Yale Cancer Center; Assistant Medical Director, Clinical Trials Office (CTO), Yale Cancer Center; Co-Leader, Leukemia and Myeloid Malignancies Clinical Research Team (CRT), Yale Cancer Center

Sub-Investigators

Last Updated
02/12/2026
Study HIC
#2000040002